Workflow
多肽与寡核苷酸药物
icon
Search documents
博腾股份连跌4天,中欧基金旗下1只基金位列前十大股东
Sou Hu Cai Jing· 2025-08-21 14:32
Group 1 - Boten Pharmaceutical Technology Co., Ltd. (stock code: 300363) provides comprehensive services for small molecule drugs, peptides, oligonucleotide drugs, proteins, conjugated drugs, and cell and gene therapies throughout the drug lifecycle, covering locations in China and several countries in Europe and the US [1] - The company has experienced a decline in stock price, with a cumulative drop of -3.44% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, China Europe Fund's China Europe Medical Health Mixed A Fund entered the top ten shareholders of Boten Pharmaceutical, marking a new investment [1] Group 2 - The China Europe Medical Health Mixed A Fund has achieved a year-to-date return of 26.29%, ranking 1357 out of 4492 in its category [1] - The fund is managed by Guo Lan and Zhao Lei, both of whom have extensive backgrounds in biomedical engineering and finance [2][5] - Guo Lan has been with China Europe Fund since October 2014 and has managed multiple funds, while Zhao Lei joined in May 2021 and currently serves as the fund manager and head of the equity research team [4][5]
多个中试平台聚集重庆 助力医药科研成果从“实验室”走向“大市场”
Group 1 - The Chongqing Liangjiang New Area has gathered multiple pilot test platforms represented by companies like Boji Pharmaceutical, Boteng Pharmaceutical, and Huaguan Biotechnology, providing "one-stop" services for the acceleration of scientific research results into industrialization [1][3] - Pilot test platforms are comprehensive support platforms that facilitate the transition of research results from laboratory development to large-scale industrial production, playing a key role in the commercialization of innovative outcomes [3] - The Ministry of Industry and Information Technology and the National Development and Reform Commission aim to cultivate over 20 pilot test capability construction platforms by 2027, serving more than 200 companies and incubating over 400 products [3] Group 2 - Boji Pharmaceutical's subsidiary, Chongqing Boji Pharmaceutical Co., Ltd., focuses on high-tech barrier and high R&D cost complex injection drug development and production, with a platform that includes R&D laboratories, quality testing centers, and sterile injection production workshops [4] - The company has incubated 8 pharmaceutical enterprises to date and aims to assist more clients in completing multiple major complex injection drugs for the first time in China, as well as achieving international registration and market expansion [4] - Boteng Pharmaceutical, also located in the Water and Soil New City, provides one-stop service solutions for small molecule drugs, peptides, oligonucleotide drugs, protein and conjugate drugs, and cell and gene therapy drugs, covering the entire lifecycle from preclinical research to drug commercialization [4] Group 3 - The Liangjiang New Area is recognized as a core area for the development of the life and health industry, currently hosting 25 various platforms related to technical services, administrative regulation, industrial incubation, scientific innovation, and clinical services [5] - The area is continuously optimizing its industrial ecosystem and improving its service system to inject momentum into the collaborative innovation development of the biopharmaceutical industry chain [5]